3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Breast
1
Conditions
Breast Neoplasms
92
Neoplasm Metastasis
10
Neoplasms
9
Breast Diseases
4
Advanced Breast Cancer
3
Recurrence
2
Neoplasms by Site
2
Carcinoma, Renal Cell
2
Breast Neoplasms, Male
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Tuberous Sclerosis
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Diseases
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Post Menopausal Women With Early Breast Cancer
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Multiple Endocrine Neoplasia Type 1
1
Mammary Neoplasms, Animal
1
Lymphoma
1
Lung Neoplasms
1
Lung Diseases
1
Lethal Congenital Contracture Syndrome 2
1
Kidney Neoplasms
1
Invasive Early Breast Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Interventions
Carboplatin
7
Pemetrexed
5
pembrolizumab
3
osimertinib
3
Erlotinib Hydrochloride
3
selpercatinib
2
pralsetinib
2
durvalumab
2
camrelizumab
2
Gemcitabine
2
Gefitinib
2
Cisplatin
2
taletrectinib
1
sotorasib
1
repotrectinib
1
patritumab
1
necitumumab
1
ficlatuzumab
1
exemestane
1
entinostat
1
cobimetinib
1
ceralasertib
1
alectinib
1
Patient Reported Outcome Measures
1
Paclitaxel
1
AZD3759
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Respiratory Tract Diseases
×
exemestane
×
Clear all
NCT01594398
2021-11-19
ENCORE110
Syndax Pharmaceuticals
Phase 1
Completed
14 enrolled